Key takeaways
Ofatumumab (Kesimpta) and dimethyl fumarate (Tecfidera) are both medications used to treat relapsing forms of multiple sclerosis (MS). However, they belong to different medication classes. Ofatumumab is a monoclonal antibody, while dimethyl fumarate is a fumaric acid derivative. Ofatumumab is administered as a subcutaneous injection, starting with weekly doses for three weeks, then monthly, whereas dimethyl fumarate is taken orally as capsules twice a day. Ofatumumab is only available as a brand-name medication, while dimethyl fumarate is available as both a brand-name and a lower-cost generic. Common side effects of ofatumumab include injection site reactions and headaches, while dimethyl fumarate often causes stomach upset and flushing. Both medications can increase the risk of infections, but dimethyl fumarate also carries a risk of liver damage and requires regular blood tests to monitor liver health.
